Pieris Pharmaceuticals Announces Dosing of First Patient in Phase I Combination Trial for PRS-343 Plus Anti-PD-L1 Immunotherapy
pharmaceutical investing Pieris Pharmaceuticals Appoints Ingmar Bruns, M.D., Ph.D., as Vice President of Clinical Development
Final Assay Results Confirm High-Grade, Near-Surface Fluorspar and Gallium Mineralisation at Monte Muambe
Homerun Resources Inc. Announces Binding Distribution Agreement with Cristal Sand Group, Securing First Commercial Sales of High-Purity Industrial Silica Sand from Santa Maria Eterna
